The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial

被引:24
|
作者
Fathi, Mojdeh [1 ]
Alavinejad, Pezhman [2 ]
Haidari, Zahra [3 ]
Amani, Reza [1 ]
机构
[1] Isfahan Univ Med Sci, Food Secur Res Ctr, Sch Nutr & Food Sci, Dept Clin Nutr, Esfahan 8173948763, Iran
[2] Ahvaz Jundishapur Univ Med Sci, Ahvaz Imam Hosp, Alimentary Tract Res Ctr, Ahvaz, Iran
[3] Isfahan Univ Med Sci, Sch Hlth, Dept Biostat & Epidemiol, Esfahan, Iran
基金
美国国家科学基金会;
关键词
Zinc supplementation; Calorie- restriction diet; Non-alcoholic fatty liver; Insulin resistance; Oxidative stress; INSULIN-RESISTANCE; NONDIABETIC PATIENTS; GLYCEMIC CONTROL; LIPID PROFILES; OBESE; DEFICIENCY; STEATOHEPATITIS; PATHOGENESIS; HOMEOSTASIS; ADAPTATION;
D O I
10.1016/j.jtemb.2020.126635
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Evidence indicates the positive effects of zinc on insulin resistance and oxidative stress in metabolic syndrome or diabetes. Non-alcoholic fatty liver disease (NAFLD) is the main hepatic manifestation of insulin resistance and metabolic syndrome. The present study is the first clinical trial that evaluated the effects of zinc supplementation on metabolic and oxidative stress status in overweight/obese patients with NAFLD undergoing calorie- restriction diet. Methods: Fifty six overweight/obese patients with confirmed mild to moderate NAFLD using ultrasonography were randomly allocated to receive 30 mg elemental zinc supplement (n = 29) or placebo (n = 27) along with weight loss diet for 12 weeks. Serum levels of zinc, homeostasis model of assessment-estimated insulin resistance (HOMA-IR), lipid profile, serum superoxide dismutasl (SOD1) and malondialdhyde (MDA) levels were assessed. Results: Serum levels of insulin, SOD1, MDA and HOMA-IR were improved in the treatment group (p < 0.05). Within group comparison showed significant reduction in serum FBS, HbA(1C), TC, LDL-c and TG in the treatment group. Conclusion: Zinc supplementation for three months improved insulin resistance and oxidative stress status in overweight/obese NAFLD patients with no beneficial effects on lipid profiles over weight loss diet.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Quercetin supplementation in non-alcoholic fatty liver disease A randomized, double-blind, placebo-controlled clinical trial
    Hosseinikia, Mahboobe
    Oubari, Farhad
    Hosseinkia, Roghaye
    Tabeshfar, Zibaneh
    Salehi, Mohammad Gharib
    Mousavian, Zeinab
    Abbasi, Mehrnaz
    Samadi, Mehnoosh
    Pasdar, Yahya
    NUTRITION & FOOD SCIENCE, 2020, 50 (06): : 1279 - 1293
  • [2] Effects of Alpha-Lipoic Acid Supplementation on Oxidative Stress Status in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Amirkhizi, Farshad
    Hamedi-Shahraki, Soudabeh
    Hosseinpour-Arjmand, Sonya
    Vaghef-Mehrabany, Elnaz
    Ebrahimi-Mameghani, Mehrangiz
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2018, 20 (09)
  • [3] The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial
    Rezaei, Seyed Mohammad Amin
    Mohammadi, Farzaneh
    Eftekhari, Mohammad Hassan
    Ejtehadi, Fardad
    Ghaem, Haleh
    Mohammadipoor, Nazanin
    BMC NUTRITION, 2023, 9 (01)
  • [4] The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial
    Seyed Mohammad Amin Rezaei
    Farzaneh Mohammadi
    Mohammad Hassan Eftekhari
    Fardad Ejtehadi
    Haleh Ghaem
    Nazanin Mohammadipoor
    BMC Nutrition, 9
  • [5] Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
    Naeini, Fatemeh
    Namkhah, Zahra
    Tutunchi, Helda
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Jazayeri-Tehrani, Seyed Ali
    Yaseri, Mehdi
    Hosseinzadeh-Attar, Mohammad Javad
    TRIALS, 2021, 22 (01)
  • [6] Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
    Fatemeh Naeini
    Zahra Namkhah
    Helda Tutunchi
    Seyed Mahdi Rezayat
    Siavash Mansouri
    Seyed Ali Jazayeri-Tehrani
    Mehdi Yaseri
    Mohammad Javad Hosseinzadeh-Attar
    Trials, 22
  • [7] The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial
    Jazayeri-Tehrani, Seyed Ali
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Qorbani, Mostafa
    Alavian, Seyed Moayed
    Daneshi-Maskooni, Milad
    Hosseinzadeh-Attar, Mohammad-Javad
    NANOMEDICINE JOURNAL, 2018, 5 (02) : 67 - 76
  • [8] No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Ilaria Barchetta
    Maria Del Ben
    Francesco Angelico
    Michele Di Martino
    Antonio Fraioli
    Giuseppe La Torre
    Rosella Saulle
    Ludovica Perri
    Sergio Morini
    Claudio Tiberti
    Laura Bertoccini
    Flavia Agata Cimini
    Francesca Panimolle
    Carlo Catalano
    Marco Giorgio Baroni
    Maria Gisella Cavallo
    BMC Medicine, 14
  • [9] No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Barchetta, Ilaria
    Del Ben, Maria
    Angelico, Francesco
    Di Martino, Michele
    Fraioli, Antonio
    La Torre, Giuseppe
    Saulle, Rosella
    Perri, Ludovica
    Morini, Sergio
    Tiberti, Claudio
    Bertoccini, Laura
    Cimini, Flavia Agata
    Panimolle, Francesca
    Catalano, Carlo
    Baroni, Marco Giorgio
    Cavallo, Maria Gisella
    BMC MEDICINE, 2016, 14
  • [10] The effect of nigella sativa supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial
    Rashidmayvan, Mohammad
    Vandyousefi, Sarvenaz
    Barati, Meisam
    Salamat, Shekoufeh
    Ghodrat, Sara
    Khorasanchi, Maryam
    Jahan-Mihan, Alireza
    Nattagh-Eshtivani, Elyas
    Mohammadshahi, Majid
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2022, 48